Skip to main navigation Skip to main content
  • KSBMR

JBM : Journal of Bone Metabolism

OPEN ACCESS
ABOUT
BROWSE ARTICLES
EDITORIAL POLICIES
FOR CONTRIBUTORS

Page Path

2
results for

"Romosozumab"

Article category

Keywords

Publication year

Authors

"Romosozumab"

Case Report

Romosozumab, which is approved for the treatment of osteoporosis, has a dual-action mechanism that promotes bone formation and inhibits bone resorption. However, its association with an increased risk of major adverse cardiovascular events, as highlighted in the ARCH I study, raises concerns. The underlying pathophysiological mechanisms, possibly involving changes in platelet dynamics, are yet to be fully elucidated. Herein, we present a case of a 60-year-old Korean woman diagnosed with immune thrombocytopenic purpura and new-onset osteoporosis, who was treated with romosozumab. Subsequent to the administration of romosozumab, there was a notable elevation in her platelet count. This observation warrants further investigation into the off-target effects of romosozumab, especially its impact on hematopoietic stem cell function and platelet dynamics. This case accentuates the imperative for more comprehensive research into the systemic effects of romosozumab, particularly its involvement in hematopoiesis and cardiovascular risk, to thoroughly understand its extensive implications for patient health.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Romosozumab

    Reactions Weekly.2025; 2043(1): 354.     CrossRef
  • 3,559 View
  • 54 Download
  • Crossref

Original Article

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
Chaiho Jeong, Jinyoung Kim, Yejee Lim, Jeonghoon Ha, Moo Il Kang, Ki-Hyun Baek
J Bone Metab 2021;28(4):317-323.
Published online November 30, 2021
DOI: https://doi.org/10.11005/jbm.2021.28.4.317
Background
Romosozumab has shown significant improvement in bone mineral density (BMD) in previously reported trials. However, BMD reflects only bone strength and does not offer insight into the bone microarchitecture. The trabecular bone score (TBS) is a non-invasive tool used to assess bone microarchitecture. Several previous studies have evaluated the efficacy of anti-osteoporotic agents using the TBS. However, data regarding the potency of romosozumab based on the TBS is lacking. This retrospective observational cohort study demonstrated the impact of romosozumab use on the TBS.
Methods
The primary outcome was the percentage change in the TBS from baseline to post-treatment. Postmenopausal osteoporosis patients were followed up for 6 and 12 months after romosozumab (210 mg monthly, N =10) and denosumab (60 mg every 6 months, N=21) or ibandronate (150 mg monthly, N=24) treatments, respectively. Patients who had previously used osteoporosis medications were included, if any the washout period was sufficient.
Results
The percentage change in TBS from baseline to post-treatment was 2.53±2.98% (6 months, N=10; P=0.04), 0.59%±3.26% (12 months, N=21; P=0.48), and -0.45±3.66% (12 months, N=24; P=0.51) in the romosozumab, denosumab, and ibandronate groups, respectively. Romosozumab demonstrated a noticeable increase in TBS, although it did not reach the least significant change (5.8%) in TBS.
Conclusions
Romosozumab improved the TBS in postmenopausal women with osteoporosis. TBS may be potentially useful for monitoring romosozumab treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology
    Angelo Semeraro, Angela Chialà, Andrea Carafa, Rosalinda Fanizzi, Elisabetta Di Tano, Maria Palmisano, Carmela Santoro, Federica Dibenedetto, Nicola Napoli
    Aging Clinical and Experimental Research.2026;[Epub]     CrossRef
  • 2. Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis
    Hooman Yahyazadeh, Tahereh Farkhondeh, Abolfazl Bagherifard, Karo Khosravi, Reza Ahmadi, Hamed Aramjoo, Babak Roshanravan, Saeed Samarghandian
    Current Medicinal Chemistry.2026; 33(14): 2794.     CrossRef
  • 3. Romosozumab improves microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis
    Michael R McClung, Donald Betah, Benjamin Z Leder, David L Kendler, Mary Oates, Jen Timoshanko, Zhenxun Wang
    Journal of Bone and Mineral Research.2025; 40(2): 193.     CrossRef
  • 4. Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
    Seunghyun Lee, Namki Hong, Sung Joon Cho, Sungjae Shin, Yumie Rhee
    Osteoporosis International.2025; 36(2): 323.     CrossRef
  • 5. Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes
    Serge Ferrari, Donald Betah, Robert G Feldman, Bente L Langdahl, Mary Oates, Jen Timoshanko, Zhenxun Wang, Ruban Dhaliwal
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): 2861.     CrossRef
  • 6. Trabecular Bone Score: From Over a Decade of Evidence to a Connected Bone Health Ecosystem
    Karen Hind, Madeleine Davies, Elena Gonzalez-Rodriguez, Didier Hans
    Osteologie.2025; 34(03): 213.     CrossRef
  • 7. Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans
    Seung-Eun Lee, Seong Hee Ahn, Beom-Jun Kim, Seung Hun Lee, Ha Young Kim, Seongbin Hong, Jung-Min Koh
    European Journal of Endocrinology.2025; 193(5): 527.     CrossRef
  • 8. Prognostic value of trabecular bone score for major osteoporotic fractures in patients with radiographic axial spondyloarthritis: a 3-year prospective cohort study
    Paweł Żuchowski, Marta Dura, Daniel Jeka, Katarzyna Gajewicz-Sawicka, Michał Kułakowski, Burkhard Muche
    Rheumatology International.2025;[Epub]     CrossRef
  • 9. Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions
    Heenam Goel, Neil Binkley, Miranda Boggild, Wing P. Chan, William D. Leslie, Eugene McCloskey, Sarah L. Morgan, Barbara C. Silva, Angela M. Cheung
    Journal of Clinical Densitometry.2024; 27(1): 101452.     CrossRef
  • 10. Update on the utility of trabecular bone score (TBS) in clinical practice for the management of osteoporosis: a systematic review by the Egyptian Academy of Bone and Muscle Health
    Yasser El Miedany, Walaa Elwakil, Mohammed Hassan Abu-Zaid, Safaa Mahran
    Egyptian Rheumatology and Rehabilitation.2024;[Epub]     CrossRef
  • 11. Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial
    Chi Chiu Mok, Kar Li Chan, Sau Mei Tse, Sammy Pak Lam Chen, Kathryn Choon Beng Tan, Wai Han Ma
    Journal of Internal Medicine.2024; 296(6): 481.     CrossRef
  • 12. Trabecular Bone Score to Enhance Fracture Risk Prediction and Treatment Strategies in Osteoporosis
    Guillaume Gatineau, Didier Hans, Karen Hind
    Seminars in Musculoskeletal Radiology.2024; 28(05): 539.     CrossRef
  • 13. Il ruolo del Trabecular Bone Score (TBS) nella gestione dell’osteoporosi primaria e secondaria
    Fabio Bioletto, Massimo Procopio, Marco Barale
    L'Endocrinologo.2024; 25(6): 634.     CrossRef
  • 14. Incident Vertebral Fractures During Romosozumab Treatment in a Patient With a Pathogenic LRP5 Variant
    Evert F S van Velsen, Mark Wijnen, Galied S R Muradin, M Carola Zillikens
    JCEM Case Reports.2024;[Epub]     CrossRef
  • 15. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension
    Didier Hans, Michele McDermott, Shuang Huang, Min Kim, Enisa Shevroja, Michael McClung
    Osteoporosis International.2023; 34(6): 1075.     CrossRef
  • 16. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Disease
    Enisa Shevroja, Jean-Yves Reginster, Olivier Lamy, Nasser Al-Daghri, Manju Chandran, Anne-Laurence Demoux-Baiada, Lynn Kohlmeier, Marie-Paule Lecart, Daniel Messina, Bruno Muzzi Camargos, Juraj Payer, Sansin Tuzun, Nicola Veronese, Cyrus Cooper, Eugene V.
    Osteoporosis International.2023; 34(9): 1501.     CrossRef
  • 17. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
    Mingwei Hu, Yifan Zhang, Jianjun Guo, Cuicui Guo, Xue Yang, Xue Ma, Hao Xu, Shuai Xiang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • 18. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
    Namki Hong, Sungjae Shin, Seunghyun Lee, Yumie Rhee
    Osteoporosis International.2023; 34(12): 2059.     CrossRef
  • 19. Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II)
    E. Carlos Rodriguez-Merchan, Alonso Moreno-Garcia, Hortensia De la Corte-Rodriguez
    SurgiColl.2023;[Epub]     CrossRef
  • 20. The efficacy of denosumab in Korean male patients with osteoporosis
    Chaiho Jeong, Jeonghoon Ha, Jinyoung Kim, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
    The Korean Journal of Internal Medicine.2022; 37(5): 1011.     CrossRef
  • 21. Update on trabecular bone score
    Telma Palomo, Patricia Muszkat, Fernanda G. Weiler, Patricia Dreyer, Cynthia M. A. Brandão, Barbara C. Silva
    Archives of Endocrinology and Metabolism.2022; 66(5): 694.     CrossRef
  • 9,177 View
  • 282 Download
  • Crossref